Spyre Therapeutics, Inc. (SYRE) Stock Score, Valuation & Financial Research

Spyre Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SYRE

Spyre Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 80.11. These figures are a research snapshot, not a buy or sell recommendation.

What Spyre Therapeutics, Inc. does

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Spyre Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of antibody-based therapies for inflammatory bowel disease and other immune-mediated diseases, relying on capital raises and financial reserves to fund its clinical trials and operations.

Products and services

  • The company is developing a pipeline of long-acting antibody candidates, including SPY001 (targeting α4β7), SPY002 (targeting TL1A), and SPY003 (targeting IL-23), intended for use as monotherapies and combination therapies.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company engages third-party service providers for clinical trial management, data collection, and the manufacturing of clinical trial materials. Source

Business strengths to evaluate

  • Proprietary antibody engineering and dose optimization platform Source

Business risks and research considerations

  • Limited operating history and lack of revenue Source
  • Dependence on key management and scientific personnel Source
  • Risks associated with clinical trial outcomes and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SYRE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 80.11
Market capitalization:
6.96B (currency not supplied)
Revenue:
USD 90.49M
Net income:
USD -178.92M
Free cash flow:
USD -169.25M
Cash:
USD 162.01M
Total debt:
USD 0.00
EPS:
USD -1.95

What stands out

  • Free cash flow is USD -169.25M, negative for the stored period.
  • The balance sheet shows USD 162.01M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -187.0% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -197.7% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 162.01M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SYRE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SYRE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SYRE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SYRE to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SYRE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research SYRE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.